<DOC>
	<DOCNO>NCT00082927</DOCNO>
	<brief_summary>RATIONALE : Ibandronate may effective reduce bone pain cause metastatic cancer . Radiation therapy use high-energy x-rays damage tumor cell . It yet know whether ibandronate effective standard treatment radiation therapy treat metastatic bone pain . PURPOSE : This phase III randomize clinical trial study ibandronate see well work compare single-dose local radiation therapy treat patient localize metastatic bone pain .</brief_summary>
	<brief_title>Single-Dose Local Radiation Therapy Compared With Ibandronate Treating Patients With Localized Metastatic Bone Pain</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare pain response 4 12 week post-treatment patient localize metastatic bone pain treat single-dose ibandronate v single-dose local radiotherapy . Secondary - Compare quality life patient treat regimen . - Correlate urinary marker osteoclast activity ( pyridinoline deoxypyridinoline ) clinical outcome patient treat regimen . OUTLINE : This randomize , open-label , crossover , multicenter study . Patients stratify accord primary tumor type participate center . Patients randomize 1 2 treatment arm . - Arm I : Patients receive single dose local radiotherapy site pain ( 8Gy/1f ) . - Arm II : Patients receive single dose ibandronate IV 15 minute . Patients achieve partial complete response 4 week crossover alternate arm . Quality life assess baseline 4 12 week . Pain assess baseline , 4 , 8 , 12 week , 6 month . Patients follow 4 , 8 , 12 week 6 12 month . Peer Reviewed Funded Endorsed Cancer Research UK PROJECTED ACCRUAL : A total 470 patient ( 235 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm primary prostate cancer OR sclerotic bone metastasis ( patient serum prostatespecific antigen &gt; 100 ng/mL ) Radiologically confirm bone metastases plain xray , isotope scan , CT scan , MRI Clinical diagnosis metastatic bone pain radiotherapy indicate Single localize metastatic bone pain AND receive optimal analgesic adjuvant drug , include nonsteroidal antiinflammatory drug , unless contraindicate Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age Over 18 Sex Male Menopausal status Not specify Performance status Not specify Life expectancy At least 3 month Hematopoietic Not specify Hepatic Not specify Renal Creatinine â‰¤ 3.0 mg/dL No hypercalcemia ( correct calcium &gt; 10.8 mg/dL ) No hypocalcemia ( correct calcium &lt; 8.2 mg/dL ) Other No know hypersensitivity ibandronate bisphosphonates No history aspirinsensitive asthma Able comply pain chart quality life assessment PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy More 4 week since prior change systemic chemotherapy No prior highdose chemotherapy ( dose intensity &gt; 3 time standard dose ) Endocrine therapy More 4 week since prior change hormonal therapy Radiotherapy See Disease Characteristics No prior external beam radiotherapy index site No prior systemic radioisotope therapy ( e.g. , strontium chloride Sr 89 samarium Sm 153 lexidronam pentasodium ) Surgery Not specify Other More 6 month since prior bisphosphonate treatment More 4 week since prior aminoglycoside antibiotic More 30 day since prior investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>bone metastasis</keyword>
	<keyword>pain</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>